US vaccine maker Moderna will officially announce its investment project in Shanghai, China in the coming days, which has been confirmed by a number of people familiar with the matter. It is said that this will be Moderna's first investment in China, which is expected to be a major project for foreign investment in Shanghai in the near future.

Moderna's investment in China is expected to set a new record for foreign investment in Shanghai. According to sources familiar with the matter, Moderna plans to embark on several projects in China and the total investment is expected to reach the level of US$1 billion. Details of the investment will be announced on the day of the signing, and more information will be available at that time.

Moderna's CEO Stephen Bansell has arrived in Shanghai for the investment signing ceremony. As the leader of the company, Bansell's arrival signifies the importance and confidence in the Chinese market, where Moderna is a biotechnology company focused on the development and production of genetically engineered drugs, and where the COVID-19 vaccine has been developed with great success worldwide.

Moderna's investment further demonstrates their commitment to the Chinese market and their willingness to work with China to achieve a win-win situation. This is also an important milestone for China, marking the development of the domestic vaccine industry and the advancement of international cooperation.

Moderna has a strong global reputation and is well recognised for their vaccine technology and innovation. This investment provides China with the opportunity to introduce advanced vaccine technology and experience, which is important for strengthening China's vaccine development capabilities and addressing public health challenges. It will also facilitate collaborative exchanges between the US and China in the biomedical field and promote global health care and scientific research.

In recent years, China has been committed to creating an open, transparent and attractive investment environment to attract more foreign companies to invest in China, and Moderna's investment is an acknowledgement of China's reform and opening up and marketization process, as well as the results of the Chinese government's active promotion of foreign investment.

According to Brand Value Network, with Moderna's investment project in China announced in Shanghai, it is believed that this will inject new vitality into the development of China's vaccine industry and make a greater contribution to the improvement of people's health and well-being. The cooperation between the two parties will further promote technological innovation, economic development, job creation and mutually beneficial cooperation between China and the United States in the field of medicine. 

Moderna's investment is also in line with the secondary indicator "Innovation Investment" under the primary indicator "Innovation Capability" in the comprehensive brand value evaluation system, which will help to improve its ranking in the World Brand Value Top 900 ranking list. Moderna's brand value is 105.693 billion CNY, ranking the 254th on "(Daguan·Keweiwei) The 3rd World Brand Value Top 900" released on March 18, 2023.

UU Brand Party 900 is bringing together the products and services of the World Brand Value Top 900 enterprises. By clicking www.brandparty900.com, get the special offers in the “Poweful Brand Union”, gain the price discount by purchasing high-quality services, quickly understand today's fashion dynamics of global brand technology, resist the loss of wealth brought about by backward counterfeit. For more details of the offer, please call the exclusive customer service hotline: 400-6868685.

 UU Brand Party 900 (www.brandparty900.com)

作者：Trina